Ben-Quan Shen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6326507/publications.pdf

Version: 2024-02-01

15 papers	626 citations	933447 10 h-index	996975 15 g-index
15 all docs	15 docs citations	15 times ranked	773 citing authors

#	Article	IF	Citations
1	Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. Breast Cancer Research and Treatment, 2022, 191, 303-317.	2.5	10
2	Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVYÂ®) Antibodyâ€“Drug Conjugate in Sprague Dawley Rats. Journal of Clinical Medicine, 2021, 10, 1323.	2.4	10
3	Characterization of Tissue Distribution, Catabolism, and Elimination of an Antiâ€“Staphylococcus aureusTHIOMAB Antibody-Antibiotic Conjugate in Rats. Drug Metabolism and Disposition, 2020, 48, 1161-1168.	3.3	9
4	Antiâ€“Lymphocyte Antigen 6 Complex, Locus E-Seco-Cyclopropabenzindol-4-One-Dimer Antibody-Drug Conjugate That Forms Adduct withÎ±1-Microglobulin Demonstrates Slower Systemic Antibody Clearance and Reduced Tumor Distribution in Animals. Drug Metabolism and Disposition, 2020, 48, 1247-1256.	3.3	3
5	Complex formation of antiâ€VEGFâ€C with VEGFâ€C released during blood coagulation resulted in an artifact in its serum pharmacokinetics. Pharmacology Research and Perspectives, 2020, 8, e00573.	2.4	3
6	Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia. MAbs, 2018, 10, 1312-1321.	5.2	13
7	Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic. Regulatory Toxicology and Pharmacology, 2016, 82, 1-13.	2.7	33
8	Bioanalytical approaches for characterizing catabolism of antibodyâ€“drug conjugates. Bioanalysis, 2015, 7, 1583-1604.	1.5	28
9	Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice. MAbs, 2014, 6, 1631-1637.	5.2	12
10	A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibodyâ€“Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer. AAPS Journal, 2014, 16, 994-1008.	4.4	72
11	Pharmacokinetics and ADME Characterizations of Antibodyâ€“Drug Conjugates. Methods in Molecular Biology, 2013, 1045, 117-131.	0.9	17
12	Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism. Current Drug Metabolism, 2012, 13, 901-910.	1.2	116
13	Maximizing tumour exposure to antiâ€neuropilinâ€1 antibody requires saturation of nonâ€tumour tissue antigenic sinks in mice. British Journal of Pharmacology, 2012, 166, 368-377.	5.4	39
14	Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibodyâ€“Drug Conjugates in Rats. Bioconjugate Chemistry, 2011, 22, 1994-2004.	3.6	177
15	Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs, 2011, 3, 376-386.	5.2	84